IMMX News

The IPO market saw an uptick in activity this past week with six IPOs raising $919 million, led by IoT solutions developer Samsara (IOT). 14 SPACs also went public. The pipeline got a boost, with six IPOs and three SPACs submitting initial filings. Samsara (IOT) priced at the high end to raise $805 million at a $12.4 billion market cap....read more

Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, raised $21 million by offering 4.2 million shares at $5, the low end of the range of $5 to $6. The company offered 0.4 million more shares than anticipated. Immix is developing a novel class of Tissue-Specific Therapeutics ("TSTx") in oncology and inflammation. Its lead asset, IMX-110, is...read more

Immix Biopharma, a Phase 1b/2a biotech developing tissue-specific therapies for solid tumors, announced terms for its IPO on Wednesday. The Los Angeles, CA-based company plans to raise $21 million by offering 3.8 million shares at a price range of $5 to $6. At the midpoint of the proposed range, Immix Biopharma would command a fully diluted market value of $76 million. Immix is...read more

The IPO market was full steam ahead this past week as 11 IPOs came to market. SPAC activity remained steady with seven blank check IPOs. New filers continue to pour into the IPO pipeline, with 15 IPOs and eight SPACs submitting initial filings. Tech consultancy Thoughtworks (TWKS) raised $774 million at a $7.0 billion market cap. This agile software developer...read more